Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals

QR Code

Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals

Objectives: Enterobacterales isolates producing β-lactamases are widespread and threaten the use of β-lactams. This study evaluated the activity of aztreonam-avibactam and comparator antimicrobial agents against Enterobacterales isolates producing common β-lactamases collected in US hospitals. Metho...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lalitagauri M Deshpande, Timothy B Doyle, Helio S Sader, Mariana Castanheira
Format:	Article
Language:	English
Published:	Elsevier 2025-09-01
Series:	Journal of Global Antimicrobial Resistance
Subjects:	Aztreonam-avibactam Ceftazidime-avibactam Esbl Carbapenemase Enterobacterales
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213716525001341
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mortality of metallo-β-lactamase-producing Enterobacterales bacteremias with combined ceftazidime–avibactam plus aztreonam vs. other active antibiotics: a multicenter target trial emulationResearch in context
by: Ivan Alfredo Huespe, et al.
Published: (2025-09-01)

Ceftazidime/avibactam as a possible treatment option for carbapenem-resistant Enterobacterales infections
by: Ana Kaftandzieva, et al.
Published: (2025-12-01)

Antimicrobial Susceptibility Testing of the Combination of Aztreonam and Avibactam in NDM-Producing <i>Enterobacterales</i>: A Comparative Evaluation Using the CLSI and EUCAST Methods
by: Linda Mei-Wah Chan, et al.
Published: (2025-07-01)

Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia
by: Yi-Tsung Lin, et al.
Published: (2025-09-01)

Mortality and clinical outcomes of ceftazidime/avibactam vs best available therapy in treating carbapenem-resistant enterobacterales infections: A retrospective cohort study
by: Nada Alhamed, et al.
Published: (2025-07-01)

Activity of β-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019–2023)
by: Helio S. Sader, et al.
Published: (2025-05-01)

Whole-Genome Analysis of NDM-Producing Providencia hangzhouensis Associated With Recurrent Bacteraemia with Rapid Development of Aztreonam-Avibactam Resistance
by: Ka Lip Chew, et al.
Published: (2025-07-01)

Infections Caused by Carbapenem-Resistant Enterobacterales: Epidemiology, Clinical Significance, and Possibilities for Antibiotic Therapy Optimization
by: S. V. Yakovlev, et al.
Published: (2020-08-01)

Clinical Eﬃcacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria
by: S. V. Yakovlev
Published: (2021-10-01)

Ceftazidime-avibactam resistance in Klebsiella pneumoniae: A growing public health concern across diverse sublineages, 2019–2024
by: Ana Beatriz Gonçalves, et al.
Published: (2025-09-01)

Multi-omics profiling of cross-resistance between ceftazidime-avibactam and meropenem identifies common and strain-specific mechanisms in Pseudomonas aeruginosa clinical isolates
by: Bartosz J. Bartmanski, et al.
Published: (2025-07-01)

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
by: Baharak Babouee Flury, et al.
Published: (2023-04-01)

Assessment of clinical effectiveness and safety of ceftazidime-avibactam in ‐treating multi-drug-resistant infections – A retrospective analysis at a tertiary care hospital in Saudi Arabia
by: Eman Merghani Ali, et al.
Published: (2025-09-01)

Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model
by: Strukova E.N., et al.
Published: (2025-03-01)

Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria
by: S. V. Nedogoda, et al.
Published: (2019-07-01)

Correction: Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
by: Baharak Babouee Flury, et al.
Published: (2025-07-01)

Economic evaluation of ceftazidime-avibactam vs. polymyxin B for treatment of hospital-acquired and ventilator-associated bacterial pneumonia
by: Jessica Matuoka, et al.
Published: (2025-07-01)

Current treatment options for infections caused by carbapenem-resistant Enterobacteriaceae in patients with hematological malignancies
by: G. A. Klyasova
Published: (2020-07-01)

Phenotypic and genotypic characterization of Beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae from patients in Kinshasa, Democratic Republic of Congo
by: Cyprien MBUNDU LUKUKULA, et al.
Published: (2025-08-01)

Nephrotoxicity of New Antibiotics: A Systematic Review
by: Panagiotis Stathopoulos, et al.
Published: (2025-07-01)

ANTIMICROBIAL THERAPY DURING CANCER TREATMENT: A CASE REPORT
by: Z. V. Grigoryevskaya, et al.
Published: (2021-08-01)

The Effectiveness of the Combined Use of Meropenem and Avibactam Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Strains in an <i>in vitro</i> Dynamic Model
by: E. N. Strukova, et al.
Published: (2025-04-01)

Cefiderocol activity against planktonic and biofilm forms of β-lactamase-producing pseudomonas aeruginosa from people with cystic fibrosis
by: Giorgia Fabrizio, et al.
Published: (2025-06-01)

Extended spectrum β-lactamase-producing Enterobacterales in live and dead birds from rural poultry farms and urban live bird markets of Bangladesh
by: Mohammed Badrul Amin, et al.
Published: (2025-07-01)

Risk Factors for Non-Carbapenemase-Producing Carbapenem-Resistant <i>Enterobacterales</i> Infections: A Retrospective Cohort Study
by: Sayaka Mabuchi, et al.
Published: (2025-05-01)

Infectious complications caused by carbapenemase-producing Enterobacterales in patients with hematological disorders
by: K. S. Tandilova, et al.
Published: (2019-10-01)

Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing Enterobacterales bacteremia
by: Jinghao Nicholas Ngiam, et al.
Published: (2025-07-01)

Infections caused by clonal spread of metallo-beta-lactamase-producing Enterobacter cloacae complex isolates at a southern Taiwan hospital
by: Cong-Tat Cia, et al.
Published: (2025-07-01)

Role of the gut microbiome in frequent gut colonization with extended-spectrum β lactamase-producing Enterobacterales among Peruvian children
by: Maya L. Nadimpalli, et al.
Published: (2025-12-01)

PHARMACOKINETICS/PHARMACODYNAMICS OF A 8-LACTAM AND /8-LACTAMASE INHIBITOR COMBINATION: A NOVEL APPROACH FOR AZTREONAM/AVIBACTAM
by: R. .. Singh, et al.
Published: (2020-05-01)

Oxacillin-Supplemented Mueller-Hinton Agar for In Vitro Inhibition of Ambler Class C β-Lactamases in Enterobacterales
by: Edgar-Costin Chelaru, et al.
Published: (2025-06-01)

One-Day Prevalence of Extended-Spectrum &beta;-Lactamase (ESBL) and Carbapenemase-Producing Bacteria in Fecal Samples from Surgical Patients: A Concerning Trend of Antibiotic Resistance
by: Sintondji K, et al.
Published: (2025-07-01)

The phenomenon of changing aztreonam susceptibility in Pseudomonas aeruginosa during formation of colistin resistance in vitro
by: Bocharova Yu.A., et al.
Published: (2025-03-01)

Genomic similarity of carbapenem-resistant Enterobacterales collected from mothers and their neonates
by: Priyanka Basak, et al.
Published: (2025-09-01)

Genomic investigation of NDM-1 producing Enterobacterales transmission in a South Korean hospital
by: Jeong-Ih Shin, et al.
Published: (2025-06-01)

CEFTOLOZANE/TAZOBACTAM AND CEFTAZIDIME/AVIBACTAM: TWO NOVEL в-LACTAM / β-LACTAMASE INHIBITOR COMBINATION AGENTS FOR THE TREATMENT OF RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS
by: J. L. Liscio, et al.
Published: (2020-05-01)

The First Experience of Combined Use of Cefepime/Sulbactam and Aztreonam in ICU Patients with Nosocomial Infections Caused by Carbapenem-Resistant Gram-Negative Microorganisms Producing Class B and D Carbapenemases
by: M. P. Suvorova, et al.
Published: (2023-02-01)

Characterisation of Citrobacter freundii and Enterobacter cloacae complex isolates co-carrying blaNDM-1 and mcr-9 from three hospitals
by: Aneta Kovarova, et al.
Published: (2025-09-01)

Emergence of ceftazidime resistance in Burkholderia pseudomallei during therapy: Clinical, phenotypic and genotypic insights from paired isolates
by: Pintip Suchartlikitwong, et al.
Published: (2025-06-01)

Tissue Distribution and Pharmacokinetic Characteristics of Aztreonam Based on Multi-Species PBPK Model
by: Xiao Ye, et al.
Published: (2025-06-01)